TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: tumour's recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change From Baseline in Weight Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Vital Sign Parameter of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent change in 24-hour urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Insulin-stimulated leg blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Differences in voice parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of bleeding days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of pain perception by visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Break up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADAS-J cog
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ocular Surface Tear Breakup Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Fluorescein Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index (OSDI) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visibility at upper endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of darolutamide from time zero to 48 hours (AUC(0-48)) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug concentration (Cmax) of darolutamide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot Flash Frequency Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local progression-free survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline intensity of breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Depression Literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trunk Impairment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five Times Sit to Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine-equivalent Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Score on Visual Analog Scale (VAS) of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cmax (Maximum Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Beta Cell Compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fall Severity Scale (FSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of clusters satisfying structure criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of higher trainees and service doctors reporting criterion process of training
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of higher trainees and service doctors rating training programmes as educationally valuable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Success rate (volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New York Heart Association (NYHA) classification for angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Laboratory Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of BMS-986256
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUC[0-T]) of BMS-986256
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) of BMS-986256
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to capecitabine and lapatinib
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of spherical and cylindrical refractive changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days outside hospital until first readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Liver iron content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive values of P3a responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negative predictive values of P3a responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of P3a responses occurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specificity of P3a responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total area strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unexplained local and systemic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Chest Pain Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative Abundance of VSL#3 Probiotic Bacterial Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of mothers who know at least 3 danger signs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: % of families who seek care from an appropriate facility
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time between onset of suspected danger signs and referral to appropriate facility
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of 6 minute walk distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in bone turnover markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite Wound Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Numerical Rating Pain Scale in shoulder mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response rate of patients who have remained progression-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical complete response rate of actinic keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: receipt of assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum observed concentration (Cmax) of DNL343 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum observed concentration (Tmax) of DNL343 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of DNL343 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of DNL343 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuation Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of OSA in pregnant women with chronic HTN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of OSA in pregnant women who are normotensive and BMI-matched to women with chronic HTN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Event-free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in urinary albumin-creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Infants Who Are Intubated Prior to Umbilical Cord Clamping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of dose limiting toxicity grade 4 or higher treatment related
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in self reported Relaxation/calm levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge about CPR
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average peak symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change in 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in LL-37
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psychomotor Vigilance Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Reasoning Questions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hepatic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood estrogen and progesterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Voluntary Ankle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area under the curve (0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[0-T]) for Atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[INF]) for Atazanavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of the CSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karlsson score enhancement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage lung deposition following 10 s breath hold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change From Baseline in Daytime Nasal Symptoms Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and local tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: cerebral oxidative metabolism (lactate/pyruvate-ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Geriatric Depression Scale (SGDS-K) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Tolerated Dose (MTD) of smac mimetic TL32711
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Minimal Residual Disease (MRD) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall access time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of factors associated with the onset of inflammatory colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of technique failure
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of the velocity of the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of adverse events (AE) grade > 2
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of drug-elicited toxicities grade > 2
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of peripheral neuropathy events grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Distance Measured During 6-minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative emergence agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean difference in Altered Mental Status (AMS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent bone marrow involvement by mastocytosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Decreased behavioral and physiologic indicators of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Functional Cognitive State
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: occurrence rate of severe complications
Endpoint domain: Adverse events/effects
Primary endpoint: Word recognition scores in quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sentence recognition scores in quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Vaginal IVRs releasing TDF-FTC
Endpoint domain: Adverse events/effects
Primary endpoint: 4 Meter Gait Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least 2 CTCAE Grades Increase in ALT or AST
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major adverse cardiac event
Endpoint domain: Adverse events/effects
Primary endpoint: Gene expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development/progression of Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Abnormal Physical Symptoms (Clinical Abnormalities)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Abnormal Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of malnourished individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Venous thrombo-embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of intracranial bleeding diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average Change in Total Circumference Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Inspiratory Capacity (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage Alcohol in Breath Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of malaria cases
Endpoint domain: Adverse events/effects
Primary endpoint: Total IV Morphine Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent changes in NF-L levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of use of colchicine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement of muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of muscle resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in frailty status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of Placental Protein 13 (PP13)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of PIGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of PAPP-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of PIBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pin site with positive culture results
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of patients alive at one year
Endpoint domain: Mortality/survival
Primary endpoint: Change in Motor Evoked Potential Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: muscle mitochondrial OXPHOS function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Diary-Based On-Time Without Dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: prevalence of spontaneous tumor-specific immunity at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: dynamics of tumor-specific immunity and immune modulatory cells during conventional treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: dynamics of tumor-specific immunity and immune modulatory cells during follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Banded neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in End-systolic Volume Indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The Positive and Negative Affect Schedule (PANAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of cGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline Values in the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effect on enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on substrate accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on autophagy-lysosomal pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on mitochondrial functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on immune and inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Test of Handwriting Skills-Revised (THS-R)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of children dying during the study period
Endpoint domain: Mortality/survival
Primary endpoint: Average weight gain in each of the treatment groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintenance of response over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum inflammation markers (CRP, SAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline for clinical safety laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral access site complication
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 2-hour Oral Glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes